400% share price surge! Is it too late to buy shares in Synairgen?

After the rapid 400% share price rise you may be wondering if it is too late to buy shares in Synairgen. Here’s what I think.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Synairgen (LON:SNG) is a drug company specialising in therapies for asthma and COPD. This morning the Synairgen share price surged over 400% after it announced positive results on a recent clinical trial relating to a new treatment for Covid-19.

The £287m company has been listed on the FTSE AIM All-Share index since 2004. Today’s share price surge took it skyrocketing past its IPO high of £1.64 a share. Is it now too late to buy shares in this exciting biotech company?

Why the price surge?

The clinical trial moving the Synairgen share price was based on its SGN001 therapy. This is a treatment designed to reduce the most serious aspects of Covid-19 in hospitalised patients. It involves the use of a protein called interferon beta that is naturally found in the body but suppressed by the coronavirus.

By inhaling this protein, the patient experiences relief and a reduction in breathlessness. The clinical trial resulted in a 79% reduction in patients developing severe disease requiring ventilation. It also showed patients were 2 to 3 times more likely to make a much better recovery. It should be noted these results have not yet been published in a peer-reviewed journal and further analysis will be needed.

A few years ago, the interferon beta therapy developed by Synairgen was being used in partnership with big pharma giant AstraZenecaAZN pulled out of the partnership when an asthma trial failed, which put the Synairgen share price into free-fall. However, Synairgen always maintained the drug therapy had potential and retained full rights after AstraZeneca pulled out. Today’s news is a major comeback from that previous disappointment.

Has the Synairgen share price got further to climb? 

With AIM shares there is always the risk that things won’t go as planned. Buying shares in pharmaceutical companies also always comes with an element of risk. Biotech and pharma is a tightly regulated industry filled with speculation, and managing cash flow can be tricky. However, this is a fantastic development for Synairgen. I think today’s news gives it positive attention that will stand it in good stead for some time to come. Synairgen was previously backed by Neil Woodford, who added it to his former UK equity fund.

When dealing with pharmaceutical treatments there are many regulatory hoops to jump through. But with the Covid-19 pandemic, everyone is eager for anything that will help bring it under control. For this reason, I don’t think it is necessarily too late to buy shares in Synairgen. Certainly, those shareholders that got in early on a speculative buy will be feeling very pleased that they did so.

This is still a risky buy but could be an exciting addition to a diversified portfolio looking for growth opportunities. I think the Synairgen share price has further to climb.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Kirsteen has no position in any of the shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

After it crashed 25%, should I buy this former stock market darling in my Stocks and Shares ISA?

Harvey Jones has a big hole in his Stocks and Shares ISA that he is keen to fill. Should he…

Read more »

happy senior couple using a laptop in their living room to look at their financial budgets
Investing Articles

How’s the dividend forecast looking for Legal & General shares in 2025 and beyond?

As a shareholder, I like to keep track of the potential dividend returns I could make from my Legal &…

Read more »

artificial intelligence investing algorithms
Investing Articles

Could buying this stock with a $7bn market cap be like investing in Nvidia in 2010?

Where might the next Nvidia-type stock be lurking in today's market? Our writer takes a look at one candidate with…

Read more »

Investing Articles

Is GSK a bargain now the share price is near 1,333p?

Biopharma company GSK looks like a decent stock to consider for the long term, so is today's lower share price…

Read more »

Snowing on Jubilee Gardens in London at dusk
Investing Articles

Could December be a great month to buy UK shares?

Christopher Ruane sees some possible reasons to look for shares to buy in December -- but he'll be using the…

Read more »

Young mixed-race couple sat on the beach looking out over the sea
Investing Articles

Sticking to FTSE shares, I’d still aim for a £1,000 monthly passive income like this!

By investing in blue-chip FTSE shares with proven business models, our writer hopes he can build sizeable passive income streams…

Read more »

Growth Shares

BT shares? I think there are much better UK stocks for the long term

Over the long term, many UK stocks have performed much better than BT. Here’s a look at two companies that…

Read more »

British Pennies on a Pound Note
Investing Articles

After a 540% rise, could this penny share keep going?

This penny share has seen mixed fortunes in recent years. Our writer looks ahead to some potentially exciting developments in…

Read more »